Suppr超能文献

乳腺癌的分子分类:从传统、过时的方式到新时代、新方法。

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

作者信息

Eliyatkın Nuket, Yalçın Evrim, Zengel Baha, Aktaş Safiye, Vardar Enver

机构信息

Department of Pathology, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey.

Department of Pathology, Erciş State Hospital, Van, Turkey.

出版信息

J Breast Health. 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr.

Abstract

Breast carcinoma comprises a group of diseases with specific clinical, histopathologic and molecular properties. Traditional classification use morphology to divide tumors into separate categories with differing behavior and prognosis. However, there are limitations of traditional classification systems, and new molecular methods are expected to improve classification systems. Molecular subtypes of breast carcinomas have been characterized in the last 11 years, and have been studied extensively. Much of the information accumulated in recent years, and molecular taxonomy seems to be still developing and undergoing change. The main question is whether new molecular techniques such as gene expression profiling will be accepted as gold standard in determining breast cancer subtypes, and whether molecular classification is useful in specific subtypes of breast cancer as it is in ductal carcinoma (nonspecific type). In addition, critical review of the literature reveals major problems such as poor definition, lack of reproducibility and lack of quality control in current molecular techniques and classifications. Therefore, current molecular approaches are not yet used in routine clinical practice and treatment guidance since they are immature and can even lead to incorrect assessment.

摘要

乳腺癌是一组具有特定临床、组织病理学和分子特性的疾病。传统分类利用形态学将肿瘤分为具有不同行为和预后的不同类别。然而,传统分类系统存在局限性,新的分子方法有望改进分类系统。乳腺癌的分子亚型在过去11年中已得到表征,并得到了广泛研究。近年来积累了大量信息,分子分类法似乎仍在发展和变化。主要问题是诸如基因表达谱分析等新的分子技术是否会被接受为确定乳腺癌亚型的金标准,以及分子分类在乳腺癌的特定亚型中是否像在导管癌(非特殊类型)中一样有用。此外,对文献的批判性审查揭示了当前分子技术和分类中存在的主要问题,如定义不明确、缺乏可重复性和缺乏质量控制。因此,目前的分子方法尚未用于常规临床实践和治疗指导,因为它们尚不成熟,甚至可能导致错误的评估。

相似文献

1
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.
J Breast Health. 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr.
2
Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review.
J Biophotonics. 2012 Apr;5(4):345-66. doi: 10.1002/jbio.201100097. Epub 2012 Jan 9.
3
Molecular classification of breast cancer: is it time to pack up our microscopes?
Pathology. 2011 Jan;43(1):1-8. doi: 10.1097/PAT.0b013e328341e0b5.
4
Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?
Hum Pathol. 2008 Apr;39(4):506-13. doi: 10.1016/j.humpath.2007.09.005. Epub 2008 Mar 4.
5
Mixture classification model based on clinical markers for breast cancer prognosis.
Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14.
6
Classifications and prognosis of breast cancer: from morphology to molecular taxonomy.
Breast J. 2010 Sep-Oct;16 Suppl 1:S15-6. doi: 10.1111/j.1524-4741.2010.00995.x.
7
Molecular classification of infiltrating breast cancer: toward personalized therapy.
Radiographics. 2014 Sep-Oct;34(5):1178-95. doi: 10.1148/rg.345130049.
8
Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.
Breast J. 2007 Mar-Apr;13(2):172-9. doi: 10.1111/j.1524-4741.2007.00393.x.

引用本文的文献

2
Drug resistance and tumor heterogeneity: cells and ensembles.
Biophys Rev. 2025 May 31;17(3):759-779. doi: 10.1007/s12551-025-01320-y. eCollection 2025 Jun.
3
Subtype- and race-specific variations in the immune landscape of breast cancer: therapeutic implications.
NPJ Breast Cancer. 2025 Jul 24;11(1):78. doi: 10.1038/s41523-025-00799-8.
5
Futility in healthcare among Mexican female patients with breast cancer in advanced stage: The patient perspective.
PLoS One. 2025 Jun 23;20(6):e0326332. doi: 10.1371/journal.pone.0326332. eCollection 2025.
7
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2458554. doi: 10.1080/14756366.2025.2458554. Epub 2025 Feb 12.
8
Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy.
Front Oncol. 2025 Jan 20;14:1490073. doi: 10.3389/fonc.2024.1490073. eCollection 2024.

本文引用的文献

1
Comprehensive molecular portraits of human breast tumours.
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
2
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.
Breast Cancer Res Treat. 2012 Aug;135(1):301-6. doi: 10.1007/s10549-012-2143-0. Epub 2012 Jul 3.
3
A three-gene model to robustly identify breast cancer molecular subtypes.
J Natl Cancer Inst. 2012 Feb 22;104(4):311-25. doi: 10.1093/jnci/djr545. Epub 2012 Jan 18.
4
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.
J Natl Cancer Inst. 2011 Apr 20;103(8):662-73. doi: 10.1093/jnci/djr071. Epub 2011 Mar 18.
5
Global cancer statistics.
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
6
Molecular classification of breast cancer: is it time to pack up our microscopes?
Pathology. 2011 Jan;43(1):1-8. doi: 10.1097/PAT.0b013e328341e0b5.
8
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast.
Am J Surg Pathol. 2010 Oct;34(10):1472-9. doi: 10.1097/PAS.0b013e3181f01916.
9
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Cancer Sci. 2011 Jan;102(1):1-8. doi: 10.1111/j.1349-7006.2010.01711.x. Epub 2010 Sep 6.
10
Breast cancer prognostic classification in the molecular era: the role of histological grade.
Breast Cancer Res. 2010;12(4):207. doi: 10.1186/bcr2607. Epub 2010 Jul 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验